Imnovid (previously Pomalidomide Celgene)
What Imnovid (previously Pomalidomide Celgene) is used for
Imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide. Imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Imnovid (previously Pomalidomide Celgene)
- Active substance
- pomalidomide
- Disease area
- Multiple Myeloma
- Medicine group
- Immunosuppressants
- ATC code
- L04AX06
- Marketing authorisation holder
- Bristol-Myers Squibb Pharma EEIG
- Authorised in the EU since
- 2013
Official information
In India
- Pomalidomide: 18 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Imnovid (previously Pomalidomide Celgene) used for?
Imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide. Imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.
What is the active substance in Imnovid (previously Pomalidomide Celgene)?
Imnovid (previously Pomalidomide Celgene) contains pomalidomide.
Who makes Imnovid (previously Pomalidomide Celgene)?
The EU marketing authorisation holder is Bristol-Myers Squibb Pharma EEIG.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU